Market Place
Sourcing Support
Pathos AI Completes Acquisition of Rain Oncology
26 Jan 2024 //
BUSINESSWIRE
Rain ends stormy year by opting to be acquired by Pathos AI
14 Dec 2023 //
FIERCE BIOTECH
Rain Oncology Enters into Agreement to be Acquired by Pathos AI
13 Dec 2023 //
GLOBENEWSWIRE
Rain Oncology Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Bios
16 Oct 2023 //
GLOBENEWSWIRE
Concentra offers to buy troubled Rain Oncology
16 Oct 2023 //
FIERCE BIOTECH
Rain Oncology Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Rain Oncology to Report Second Quarter 2023 Financial Results
26 Jul 2023 //
GLOBENEWSWIRE
Rain lays off 65% of workforce after phase 3 fail
30 May 2023 //
FIERCE BIOTECH
Rain Oncology Provides Company Update and Outlines Strategic Priorities
30 May 2023 //
GLOBENEWSWIRE
Rain`s shares fall 80% as lone asset fails to improve survival
23 May 2023 //
FIERCE BIOTECH
Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology
23 Jan 2023 //
PRESS RELEASE
Rain Therapeutics Inc. Announces Name Change to Rain Oncology Inc.
29 Dec 2022 //
PRESS RELEASE
Rain Therapeutics Announces a Poster Presentation at Symposium
23 Nov 2022 //
GLOBENEWSWIRE
Rain Therapeutics to Participate in Piper Sandler’s 34th Annual Conference
18 Nov 2022 //
GLOBENEWSWIRE
Rain Announces an Oral Presentation at the Connective Tissue Oncology
17 Nov 2022 //
GLOBENEWSWIRE
Rain Therapeutics Reports 3Q 2022 Financial Results & Recent Progress
10 Nov 2022 //
GLOBENEWSWIRE
Rain reports initial Phase II data for solid tumour therapy
07 Nov 2022 //
CLINICALTRIALSARENA
Rain Therapeutics Provides Interim Analysis of Ph2 Basket Trial of Milademetan
04 Nov 2022 //
GLOBENEWSWIRE
Rain Therapeutics Announces $50 Million Registered Offering of Common Stock
04 Nov 2022 //
GLOBENEWSWIRE
Rain Therapeutics to Report Third Quarter 2022 Financial Results
27 Oct 2022 //
GLOBENEWSWIRE
Rain Therapeutics Announces a Poster Presentation at EORTC/AACR/NCI Symposium
26 Oct 2022 //
GLOBENEWSWIRE
Rain Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference
31 Aug 2022 //
GLOBENEWSWIRE
Rain Therapeutics Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
PRESS RELEASE
Rain Tx Completes Enrollment in PIII MANTRA Trial for Milademetan in Liposarcoma
04 Aug 2022 //
GLOBENEWSWIRE
Rain Therapeutics Completes Enrollment in PIII MANTRA Trial for Milademetan
04 Aug 2022 //
GLOBENEWSWIRE
Rain Therapeutics to Report Second Quarter 2022 Financial Results
21 Jul 2022 //
PRESS RELEASE
The Rain Therapeutics Inc. Co-Founder Just Bought US$57k Worth Of Shares
07 Jun 2022 //
SIMPLYWALL STREET
Rain Therapeutics to Present on Milademetan at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
18 May 2022 //
PRESS RELEASE
Rain Therapeutics Reports First Quarter 2022 Financial Results
04 May 2022 //
GLOBENEWSWIRE
Rain Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
03 Mar 2022 //
GLOBENEWSWIRE
Rain Therapeutics Doses First Patient in Phase 2 Basket Trial of Milademetan
19 Nov 2021 //
GLOBENEWSWIRE
Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3)
09 Nov 2021 //
GLOBENEWSWIRE
Rain Therapeutics Hosting Research and Development (R&D) Day
25 Oct 2021 //
GLOBENEWSWIRE
Rain Therapeutics to Present on Milademetan at the 2021 AACR-NCI-EORTC
04 Oct 2021 //
GLOBENEWSWIRE
RAIN Group Releases New Guide “36 Powerful Sales Questions for Life Sciences”
04 Oct 2021 //
BIOSPACE
Rain Therapeutics to Present on Milademetan at the 2021 AACR-NCI-EORTC
04 Oct 2021 //
GLOBENEWSWIRE
RAIN Group Releases New Guide “36 Powerful Sales Questions for Life Sciences”
04 Oct 2021 //
BIOSPACE
Rain Therapeutics Presents Non-Clinical Data on Milademetan in MPM
08 Sep 2021 //
GLOBENEWSWIRE
Rain Therapeutics Announces Collaboration with Tempus for Genomic
03 Jun 2021 //
GLOBENEWSWIRE
Vedanta Biosciences taps Big Pharma vet Jeffrey Silber as CMO
18 Sep 2020 //
ENDPTS
